Notice of allowance of patent in Canada
Fusion Antibodies plc has received a notice of allowance from the Canadian Intellectual Property Office for its patent application no. 3,115,150, titled "Antibody Library and Method," which covers two antibody families and their design methodology. This patent, once granted, is expected to complement the company's "Opti" designed antibody libraries used for discovery, affinity maturation, and sequence optimisation. Fusion is also pursuing similar patent applications in Europe and China for its OptiMAL® Library. The notice of allowance signifies patentability, with the formal grant anticipated upon completion of administrative requirements and payment of fees.
Select text to share a quote on X · sign in to keep highlights & notes in your FAB notes
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Canadian Intellectual Property Office has issued a notice of allowance in respect of the Company's Canadian patent application no. 3,115,150 (the "Patent Application").
The Patent Application entitled "Antibody Library and Method", covers two families of antibodies, and the method for the design of such antibody libraries. The patent, once granted, is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation.
The Company is also progressing additional patent applications in respect of the OptiMAL® Library in Canada and several other territories worldwide including Europe and China.
Receipt of a notice of allowance indicates that the claims in the Patent Application are patentable and does not in itself represent a grant of patent rights. Fusion anticipates that the patent will be granted upon completion of certain administrative requirements, including payment of the Patent Application, in due course.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.